Pediatrix Medical Group, Inc. (MD) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. Pediatrix Medical Group, Inc. is a leading provider of physician services, including newborn, maternal-fetal, and pediatric subspecialty care, operating a national network of affiliated physicians in 36 states. The company has recently completed a strategic shift to exit almost all affiliated office-based practices (completed by December 31, 2024) to focus on hospital-based neonatal and maternal-fetal medicine services.
Key Financial Metrics
| Metric (in thousands, except per share) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $468,844 | $504,296 | $927,203 | $999,397 |
| Net Income (Loss) | $39,260 | $(153,025) | $59,997 | $(148,990) |
| Diluted EPS | $0.46 | $(1.84) | $0.70 | $(1.79) |
| Adjusted EBITDA | $73,246 | $57,857 | $122,427 | $95,068 |
| Operating Margin | 12.8% | (31.3)% | 9.9% | (14.2)% |
| Cash and Cash Equivalents | $224,732 | $19,402 | $224,732 | $19,402 |
| Total Debt (Principal) | $606,300 | $606,300 | $606,300 | $606,300 |
| Working Capital | $272,007 | $205,497 | $272,007 | $205,497 |
Note: Total Debt includes $400.0 million in 2030 Notes and $206.3 million in Term A Loan. Working Capital calculated as Current Assets ($613,050) minus Current Liabilities ($341,043).
Material Changes vs. Prior Period
- Profitability Turnaround: The company reported a net income of $39.3 million for Q2 2025, a significant improvement from a net loss of $153.0 million in Q2 2024. The prior year loss was heavily impacted by a $154.2 million goodwill impairment, $27.8 million in long-lived asset impairments, and a $10.9 million loss on disposal of businesses, none of which occurred in Q2 2025.
- Revenue Trends: Net revenue decreased 7.0% year-over-year in Q2 2025 to $468.8 million. This decline is primarily due to the exit of office-based practices (non-same unit activity). However, same-unit revenue increased 6.4%, driven by higher patient acuity in neonatology, improved collections, and increased administrative fees from hospital partners.
- Expense Management: Practice salaries and benefits decreased 9.6% to $323.5 million, and practice supplies decreased 36.3% to $20.6 million, largely reflecting the reduction in practice footprint. Transformational and restructuring expenses dropped to $3.8 million from $13.6 million in the prior year.
- Liquidity Improvement: Cash and cash equivalents increased significantly to $224.7 million from $19.4 million at the end of Q2 2024. Days Sales Outstanding (DSO) improved to 46.4 days from 49.5 days in the prior year period.
Guidance, Outlook, and Risks
- Strategic Focus: Management continues to focus on hospital-based neonatal and maternal-fetal medicine services following the exit of primary and urgent care service lines. The company expects to maintain compliance with financial covenants throughout 2025.
- Regulatory Risks: The company faces potential impacts from the "No Surprises Act" (NSA) regarding out-of-network reimbursement rates and independent dispute resolution (IDR) outcomes. Additionally, recent Medicaid reform legislation (One Big Beautiful Bill Act signed July 4, 2025) introduces work requirements and cost-sharing changes that could affect reimbursement levels, though the ultimate impact is uncertain.
- Legal and Contingencies: The company maintains professional liability insurance but self-insures a portion of this risk. Total professional liability risk exposure was $274.8 million as of June 30, 2025. The company is subject to routine government audits and medical malpractice litigation, which could materially affect financial results if resolved unfavorably.
- Capital Allocation: The company has $450.0 million available on its revolving credit line and intends to use funds from operations and available credit to finance working capital, acquisitions, and share repurchases. A nominal amount of shares was repurchased in Q2 2025 to satisfy tax withholding obligations.
Investor Verification Checklist
- Same-Unit Growth Sustainability: Verify if the 6.4% same-unit revenue growth is sustainable given the shift in payor mix and potential Medicaid reimbursement changes.
- DSO and Collection Trends: Monitor Days Sales Outstanding (currently 46.4 days) to ensure collection efficiency remains stable as the company navigates the No Surprises Act.
- Debt Covenants: Confirm continued compliance with the minimum interest coverage ratio and maximum consolidated net leverage ratio under the Amended Credit Agreement.
- Professional Liability Exposure: Review the adequacy of the $274.8 million liability reserve for professional liability claims and the performance of the captive insurance subsidiary.
- Restructuring Costs: Track remaining transformational and restructuring expenses to ensure they align with the strategic exit of non-core practices.